28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
In this population, among those who progressed to dementia, 60% progressed to AD and 33% to VaD. 2 key findings →
Design: longitudinal study Participants: 2,963 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Pooled clinical and neuropathologic data from 3 prospective cohort studies indicate that TBI with LOC is associated with risk for Lewy body accumulation, progression of parkinsonism, and PD, but not dementia, AD, neuritic plaques, or neurofibrillary tangles. 5 key findings →
Design: cohort study Participants: 7,130 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cancer survivors had a lower risk of Alzheimer's disease than those without cancer, and patients with Alzheimer's disease had a lower risk of incident cancer. 5 key findings →
Design: cohort study Participants: 1,278 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This review suggests a substantial proportion of patients with heart failure have concomitant cognitive problems. 4 key findings →
Design: meta-analysis Participants: 8,411 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Previously increased blood pressure may increase the risk for dementia by inducing small-vessel disease and white-matter lesions. 5 key findings →
Design: longitudinal study Participants: 382 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The current study suggests that the degree of HPA hyperactivity can vary considerably across patient groups. 5 key findings →
Participants: 18,454 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The authors assessed the association of smoking with dementia and cognitive decline in a meta-analysis of 19 prospective studies with at least 12 months of follow-up. 3 key findings →
Design: meta-analysis Participants: 26,374 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Stroke is a strong, independent, and potentially modifiable risk factor for all-cause dementia. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our findings support the hypothesis that depression is a risk factor for dementia and suggest that recurrent depression is particularly pernicious. 3 key findings →
Design: longitudinal study Participants: 1,239 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
High blood pressure increases the risks of stroke, dementia, and neurocognitive dysfunction. 2 key findings →
Participants: 124 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Prediabetes was positively associated with risk of all-cause mortality and the incidence of cardiovascular outcomes, CHD, stroke, chronic kidney disease, cancer and dementia. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The association of depression with prevalent MCI and with progression from MCI to dementia, but not with incident MCI, suggests that depression accompanies cognitive impairment but does not precede it. 4 key findings →
Design: cohort study Participants: 2,160 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A single traumatic brain injury is associated with an increased risk of dementia and, in a proportion of patients surviving a year or more from injury, the development of hallmark Alzheimer's disease-like pathologies. 4 key findings →
Design: longitudinal study Participants: 52 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Letters18 February 2020Geographic Variation in Prevalence of Adult Obesity in China: Results From the 2013–2014 National Chronic Disease and Risk Factor SurveillanceXiao Zhang, MD, PhD, Mei Zhang, MD, PhD, Zhenping Zhao, MD, Zhengjing Huang, MPH, Qian Deng, MD, PhD, Yichong Li, MD, PhD, An Pan, MD, PhD, Chun Li, MD, Zhihua Chen, MD, Maigeng Zhou, MD, PhD, Chao Yu, PhD, Alfred Stein, PhD, Peng Jia, PhD*, and Limin Wang, MPH*Xiao Zhang, MD, PhDNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (X.Z., M.Z., Z.Z., Z.H., Q.D., Y.L., C.L., Z.C., M.Z., L.W.), Mei Zhang, MD, PhDNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (X.Z., M.Z., Z.Z., Z.H., Q.D., Y.L., C.L., Z.C., M.Z., L.W.), Zhenping Zhao, MDNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (X.Z., M.Z., Z.Z., Z.H., Q.D., Y.L., C.L., Z.C., M.Z., L.W.), Zhengjing Huang, MPHNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (X.Z., M.Z., Z.Z., Z.H., Q.D., Y.L., C.L., Z.C., M.Z., L.W.), Qian Deng, MD, PhDNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (X.Z., M.Z., Z.Z., Z.H., Q.D., Y.L., C.L., Z.C., M.Z., L.W.), Yichong Li, MD, PhDNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (X.Z., M.Z., Z.Z., Z.H., Q.D., Y.L., C.L., Z.C., M.Z., L.W.), An Pan, MD, PhDSchool of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (A.P.), Chun Li, MDNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (X.Z., M.Z., Z.Z., Z.H., Q.D., Y.L., C.L., Z.C., M.Z., L.W.), Zhihua Chen, MDNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (X.Z., M.Z., Z.Z., Z.H., Q.D., Y.L., C.L., Z.C., M.Z., L.W.), Maigeng Zhou, MD, PhDNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Observationally, CVDs were associated with risk of all incident outcomes in meta-analyses, with hazard ratios up to 7.00 (95% confidence interval [CI]: 6.20, 7.92). 5 key findings →
Design: meta-analysis Participants: 10,373 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Enrolment took place between March 2023 and May 2023. 3 key findings →
Design: randomized controlled trial Participants: 4,533 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Despite differences in CVR management within the countries considered, it was possible to design and implement the HATICE multidomain intervention. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
The incidence of MCR is high in older adults. 2 key findings →
Design: cohort study Participants: 3,128 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher WMH volume was associated with older age, lower CSF amyloid-β levels, hypertension, and smoking history (all p ≤ 0.001), as well as cognitive status (MCI, p < 0.001; dementia, p = 0.008), but not with CSF tau levels. 5 key findings →
Design: longitudinal study Participants: 1,803 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Twenty-five meta-analyses published between 2007 and 2021 were included. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's disease and related dementias is a major public health burden-compounding over upcoming years due to longevity. 1 key finding →
Design: longitudinal study Participants: 30,097 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We identified 1,041 incident all-cause dementia cases in 4,283 participants over 37,102 person-years of follow-up. 5 key findings →
Design: cohort study Participants: 4,283 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 5,699 participants (mean age: 70±8 years), we observed total PM2.5 concentrations ranging from 16 to 206 μg/m3. 5 key findings →
Design: longitudinal study Participants: 5,699 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Evidence on the association between air pollution and dementia is accumulating but still inconclusive, and the potential effect modification by genetics is unclear. 2 key findings →
Design: cohort study Participants: 227,840 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In total, 20 articles were selected for review; 18 included results on the long-term effects of PM2.5 on dementia, 13 on AD, and eight on VaD. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →